Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphomaGlobeNewsWire • 08/24/21
Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMNZacks Investment Research • 08/04/21
Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMAGlobeNewsWire • 08/03/21
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular eventsPRNewsWire • 08/02/21
Novartis' TGFβ Targeted Antibody Secures FDA Orphan Drug Tag For Pancreatic CancerBenzinga • 07/27/21
Novartis CEO says Covid-related doctor visit delays likely impacting cancer diagnosis ratesCNBC • 07/21/21
Novartis AG (NVS) CEO Vas Narasimhan on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/21/21
Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.GlobeNewsWire • 07/21/21
Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equityGlobeNewsWire • 07/20/21
Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta VariantBenzinga • 07/08/21
